Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Queensland Health
Harvard Business School
Chubb
Citi
Teva
Deloitte
Medtronic

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022569

« Back to Dashboard

NDA 022569 describes LAZANDA, which is a drug marketed by Elefsee Pharms Intl and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug. Additional details are available on the LAZANDA profile page.

The generic ingredient in LAZANDA is fentanyl citrate. There are thirty-one drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.
Summary for 022569
Tradename:LAZANDA
Applicant:Elefsee Pharms Intl
Ingredient:fentanyl citrate
Patents:6
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 022569
Mechanism of ActionFull Opioid Agonists
Suppliers and Packaging for NDA: 022569
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569 NDA Depomed, Inc. 13913-009 N 13913-009-01
LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569 NDA Depomed, Inc. 13913-010 N 13913-010-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.1MG BASE
Approval Date:Jun 30, 2011TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Apr 20, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
Patent:➤ Try a Free TrialPatent Expiration:Oct 3, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Patent:➤ Try a Free TrialPatent Expiration:Jan 16, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

Expired US Patents for NDA 022569

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Elefsee Pharms Intl LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569-002 Jun 30, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Elefsee Pharms Intl LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569-001 Jun 30, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Deloitte
Moodys
Healthtrust
QuintilesIMS
Johnson and Johnson
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.